Regeneración del disco intervertebral lumbar mediante MSV*”*Células progenitoras de médula ósea autóloga, expandidas Ex Vivo” con procedimiento GMP del Instituto de Biología y Genética Molecular de Valladolid
- Conditions
- Pacientes con enfermedad degenerativa de uno o dos discos lumbares con predominio de dolor lumbar y/o citalagia persistente tras tratamiento conservador (médico y fisioteràpico) de mas de 6 meses de evolución.
- Registration Number
- EUCTR2008-001191-68-ES
- Lead Sponsor
- Institut de Terapia Regenerativa Tissular (ITRT)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are activated by autologous bone marrow progenitor cell therapy in lumbar disc regeneration?
How does GMP-compliant ex vivo expansion of bone marrow-derived MSCs compare to standard surgical interventions for degenerative disc disease?
Which biomarkers correlate with successful intervertebral disc regeneration in autologous MSC-based therapies?
What are the long-term safety profiles of GMP-grade bone marrow progenitor cell injections in spinal disorders?
Are there combination therapies involving MSCs and growth factors (e.g., TGF-β, IGF-1) for treating chronic lumbar disc degeneration?